ATE400030T1 - Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität - Google Patents
Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenitätInfo
- Publication number
- ATE400030T1 ATE400030T1 AT02726112T AT02726112T ATE400030T1 AT E400030 T1 ATE400030 T1 AT E400030T1 AT 02726112 T AT02726112 T AT 02726112T AT 02726112 T AT02726112 T AT 02726112T AT E400030 T1 ATE400030 T1 AT E400030T1
- Authority
- AT
- Austria
- Prior art keywords
- reduced immunogenicity
- cell
- pitopes
- identifying
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01103954 | 2001-02-19 | ||
EP01105777 | 2001-03-08 | ||
EP01106536 | 2001-03-15 | ||
EP01106538 | 2001-03-15 | ||
EP01106899 | 2001-03-20 | ||
EP01107012 | 2001-03-20 | ||
EP01107568 | 2001-03-27 | ||
EP01110220 | 2001-04-25 | ||
EP01113228 | 2001-05-30 | ||
EP01124965 | 2001-10-19 | ||
EP01126859 | 2001-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE400030T1 true ATE400030T1 (de) | 2008-07-15 |
Family
ID=27581535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02726112T ATE400030T1 (de) | 2001-02-19 | 2002-02-18 | Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität |
Country Status (14)
Country | Link |
---|---|
US (1) | US7430476B2 (de) |
EP (2) | EP1366455B1 (de) |
JP (1) | JP4279554B2 (de) |
KR (1) | KR100899970B1 (de) |
CN (1) | CN100404673C (de) |
AT (1) | ATE400030T1 (de) |
AU (1) | AU2002256624B2 (de) |
CA (1) | CA2438652A1 (de) |
ES (1) | ES2309167T3 (de) |
HU (1) | HUP0303199A2 (de) |
MX (1) | MXPA03007316A (de) |
PL (1) | PL362414A1 (de) |
WO (1) | WO2002069232A2 (de) |
ZA (1) | ZA200307324B (de) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1037927B1 (de) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
JP2002544522A (ja) * | 1999-05-14 | 2002-12-24 | マクギル ユニバーシティー | タンパク質間相互作用並びに相互作用するタンパク質および相互作用部位のアミノ酸配列を同定する方法 |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
DE60129695T2 (de) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
CN1330664C (zh) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN100503639C (zh) | 2001-05-03 | 2009-06-24 | 默克专利有限公司 | 重组肿瘤特异性抗体及其应用 |
DK200101090A (da) * | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
CA2466592A1 (en) * | 2001-11-12 | 2003-05-22 | Koen Hellendoorn | Modified anti-tnf alpha antibody |
CN1592633A (zh) * | 2001-11-29 | 2005-03-09 | 默克专利有限公司 | 羧肽酶g2的t细胞表位 |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
WO2003072746A2 (en) * | 2002-02-26 | 2003-09-04 | Genencor International, Inc. | Subtilisin carlsberg proteins with reduced immunogenicity |
KR20050010898A (ko) * | 2002-06-11 | 2005-01-28 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 브리오딘 1 |
CN1675242A (zh) * | 2002-08-09 | 2005-09-28 | 默克专利有限公司 | 促红细胞生成素中的t-细胞表位 |
AU2003290563A1 (en) * | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
EP1578397B1 (de) * | 2002-11-15 | 2012-12-26 | Genmab A/S | Humane monoklonale antikörper gegen cd25 |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
AU2004245038A1 (en) * | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
WO2004113387A2 (en) * | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Tumour necrosis factor receptor molecules with reduced immunogenicity |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
NZ546173A (en) | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
CN1898267B (zh) * | 2003-11-01 | 2012-05-23 | 默克专利股份有限公司 | 修饰的抗cd52抗体 |
WO2005056759A2 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
DE602004025506D1 (de) * | 2003-12-18 | 2010-03-25 | Genencor Int | Beta-lactamase-cd4+-t-zellepitope |
WO2005063820A2 (en) * | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
DK1699821T3 (da) * | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
WO2005070967A2 (en) * | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
PT1737961E (pt) | 2004-03-19 | 2013-08-26 | Merck Patent Gmbh | Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN101987870B (zh) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
WO2006029094A2 (en) * | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2845865A1 (de) | 2004-11-12 | 2015-03-11 | Xencor Inc. | FC-Varianten mit Veränderter Bindung zu FCRN |
US7589179B2 (en) * | 2004-12-09 | 2009-09-15 | Merck Patent Gmbh | IL-7 variants with reduced immunogenicity |
AU2012209017B2 (en) * | 2005-02-03 | 2014-06-26 | Antitope Limited | Human antibodies and proteins |
US20080206239A1 (en) * | 2005-02-03 | 2008-08-28 | Antitope Limited | Human Antibodies And Proteins |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
ES2384055T3 (es) | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
PT2270050E (pt) | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
DK2463305T3 (en) | 2006-01-12 | 2016-08-29 | Alexion Pharma Inc | Antibodies to OX-2 / CD200 and uses thereof |
US20080095756A1 (en) * | 2006-09-05 | 2008-04-24 | Biosynexus Incorporated | Compositions Comprising Lysostaphin Variants And Methods Of Using The Same |
JP2010530895A (ja) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス,インク. | 修飾毒素 |
JP5341889B2 (ja) | 2007-07-17 | 2013-11-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作された抗αVインテグリンハイブリッド抗体 |
EP2183353B1 (de) | 2007-08-22 | 2015-04-29 | ProBioGen AG | Kultursystem und verfahren zum testen von immunogenität und immunfunktion in vitro |
EP3575317A1 (de) | 2007-12-26 | 2019-12-04 | Xencor, Inc. | Fc-varianten mit veränderter bindung zu fcrn |
WO2009110944A1 (en) | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
PL2293804T3 (pl) | 2008-05-29 | 2014-03-31 | Univ Bologna Alma Mater Studiorum | Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania |
ES2940466T3 (es) | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
CA2759333A1 (en) * | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
WO2010124259A1 (en) * | 2009-04-24 | 2010-10-28 | Centre Hospitalier Universitaire Sainte-Justine | Allosteramers for tnf receptors and uses thereof |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2496257A4 (de) * | 2009-11-05 | 2013-02-27 | Cephalon Australia Pty Ltd | Behandlung von krebs mit mutierten kras- oder braf-genen |
JP6012473B2 (ja) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
WO2011109556A2 (en) | 2010-03-04 | 2011-09-09 | Pfenex Inc. | Method for producing soluble recombinant interferon protein without denaturing |
WO2011123570A2 (en) | 2010-04-01 | 2011-10-06 | Pfenex Inc. | Methods for g-csf production in a pseudomonas host cell |
SG185383A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
KR20130036276A (ko) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 보체 결합 3의 C3d 조각에 대한 항체들 |
JP2012041316A (ja) * | 2010-08-23 | 2012-03-01 | Akita Univ | 新規ペプチド並びに分子シャペロン誘導剤及び抗がん剤 |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
LT2672994T (lt) | 2011-02-11 | 2018-07-25 | Merck Patent Gmbh | Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui |
US9359405B2 (en) * | 2011-03-14 | 2016-06-07 | Phlogo Aps | Antagonists of the interleukin-1 receptor |
EP2694106B1 (de) | 2011-04-01 | 2017-12-13 | ImmunoGen, Inc. | Verfahren zur erhöhung der wirksamkeit einer folr1-krebstherapie |
WO2012142142A2 (en) | 2011-04-12 | 2012-10-18 | Temple University - Of The Commonwealth System Higher Education | Adiponectin receptor agonists and methods of use |
EP2793944A4 (de) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | Immunoglobuline und varianten gegen pathogene mikroben |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US20130216530A1 (en) * | 2012-02-02 | 2013-08-22 | Exagen Diagnostics, Inc. | Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants |
RU2668824C2 (ru) | 2012-08-31 | 2018-10-02 | Иммьюноджен Инк. | Диагностические анализы и наборы для детекции фолатного рецептора 1 |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
WO2014150600A2 (en) | 2013-03-15 | 2014-09-25 | Angelica Therapeutics, Inc. | Modified toxins |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
BR112016003665B1 (pt) | 2013-08-30 | 2024-01-09 | Immunogen, Inc | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a um epítopo do receptor de folato 1, polinucleotídeo, vetor,célula hospedeira procariótica ou de levedura, composição, seus usos e métodos in vitro para detecção da expressão do receptor de folato 1 e identificação de um câncer |
WO2015074048A1 (en) * | 2013-11-18 | 2015-05-21 | Siscapa Assay Technologies, Inc. | Measurement of gamma-carboxylation of proteins |
CA2943569C (en) | 2014-03-27 | 2021-02-23 | British Columbia Cancer Agency Branch | T-cell epitope identification |
JP7059003B2 (ja) | 2014-05-14 | 2022-04-25 | トラスティーズ・オブ・ダートマス・カレッジ | 脱免疫化リゾスタフィン及び使用方法 |
CN113768952A (zh) | 2014-11-05 | 2021-12-10 | 纪念斯隆-凯特林癌症中心 | 选择用于过继细胞疗法的t细胞系及其供体的方法 |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
WO2017040832A1 (en) * | 2015-09-01 | 2017-03-09 | The Administrators Of The Tulane Educational Fund | A method for cd4+ t-cell epitope prediction using antigen structure |
US10172875B2 (en) | 2015-09-17 | 2019-01-08 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
KR101897122B1 (ko) * | 2016-03-09 | 2018-09-10 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
US10913772B2 (en) * | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
AU2017340028A1 (en) * | 2016-10-04 | 2019-05-23 | The Council Of The Queensland Institute Of Medical Research | Peptide libraries and methods of use |
KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
GB201618432D0 (en) * | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
CN109206482B (zh) * | 2018-09-30 | 2021-12-10 | 福建蓝昊生物科技有限公司 | 一种抑制消化道炎症的海藻源短肽及其应用 |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
EP3757127A1 (de) * | 2019-06-28 | 2020-12-30 | Institute for Research in Biomedicine | Entimmunisierte antikörper mit bindung an alpha-4-integrin und verwendungen davon |
CN110694056B (zh) * | 2019-10-25 | 2023-05-05 | 四川农业大学 | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 |
EP4144375A1 (de) * | 2020-04-29 | 2023-03-08 | Onegene Biotechnology Inc. | Neuartiges proteinkonjugat und verwendung davon zur vorbeugung oder behandlung von nichtalkoholischer steatohepatitis, adipositas und diabetes |
CN112457399B (zh) * | 2020-12-19 | 2023-09-01 | 上海佰君生物科技有限公司 | 一种人免疫球蛋白g的提纯方法 |
CN112480245B (zh) * | 2020-12-19 | 2023-08-18 | 上海佰君生物科技有限公司 | 一种疏水性环状肽配基纯化人免疫球蛋白g的应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763257A (en) | 1984-05-29 | 1998-06-09 | Genencor International, Inc. | Modified subtilisins having amino acid alterations |
US5972682A (en) | 1984-05-29 | 1999-10-26 | Genencor International, Inc. | Enzymatically active modified subtilisins |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
US4914031A (en) | 1987-04-10 | 1990-04-03 | Amgen, Inc. | Subtilisin analogs |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0555205B1 (de) | 1989-01-31 | 2000-11-29 | RUBIN, Jeffrey S | Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JPH03505976A (ja) | 1989-05-17 | 1991-12-26 | アムジエン・インコーポレーテツド | 多重突然変異スブチリシン |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US5945397A (en) | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0438310A1 (de) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Verfahren zur Herstellung von rekombinanten Immunoglobulinen |
US5986070A (en) | 1990-04-06 | 1999-11-16 | Amgen Inc. | Production of biologically active NGF proteins |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
PT706563E (pt) | 1993-06-29 | 2005-01-31 | Chiron Corp | Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5618714A (en) | 1993-12-15 | 1997-04-08 | Eli Lilly And Company | Methods for producing protein C |
WO1995025540A1 (en) | 1994-03-23 | 1995-09-28 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6008328A (en) | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5869330A (en) | 1995-06-05 | 1999-02-09 | Whitehead Institute For Biomedical Research | DNA encoding a novel serum protein produced exclusively in adipocytes |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
EA004791B1 (ru) | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ob и способы их применения |
US5741772A (en) | 1997-02-03 | 1998-04-21 | Amgen Inc. | Neurotrophic factor NNT-1 |
IL132325A (en) | 1997-04-28 | 2005-07-25 | Lilly Co Eli | Activated protein c formulations |
JP2002512624A (ja) * | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
CA2352538A1 (en) * | 1998-11-30 | 2000-06-08 | Eli Lilly And Company | Erythropoietic compounds |
EP1051432B1 (de) * | 1998-12-08 | 2007-01-24 | Biovation Limited | Verfahren zur verminderung der immunogenität von proteinen |
BR0007414A (pt) | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
-
2002
- 2002-02-18 KR KR1020037010860A patent/KR100899970B1/ko not_active IP Right Cessation
- 2002-02-18 ES ES02726112T patent/ES2309167T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP02726112A patent/EP1366455B1/de not_active Expired - Lifetime
- 2002-02-18 CA CA002438652A patent/CA2438652A1/en not_active Abandoned
- 2002-02-18 HU HU0303199A patent/HUP0303199A2/hu unknown
- 2002-02-18 EP EP08011838A patent/EP1998266A3/de not_active Withdrawn
- 2002-02-18 JP JP2002568279A patent/JP4279554B2/ja not_active Expired - Lifetime
- 2002-02-18 CN CNB028051572A patent/CN100404673C/zh not_active Expired - Fee Related
- 2002-02-18 MX MXPA03007316A patent/MXPA03007316A/es active IP Right Grant
- 2002-02-18 US US10/468,496 patent/US7430476B2/en not_active Expired - Lifetime
- 2002-02-18 PL PL02362414A patent/PL362414A1/xx not_active Application Discontinuation
- 2002-02-18 WO PCT/EP2002/001688 patent/WO2002069232A2/en active IP Right Grant
- 2002-02-18 AT AT02726112T patent/ATE400030T1/de not_active IP Right Cessation
- 2002-02-18 AU AU2002256624A patent/AU2002256624B2/en not_active Expired
-
2003
- 2003-09-18 ZA ZA2003/07324A patent/ZA200307324B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2438652A1 (en) | 2002-09-06 |
MXPA03007316A (es) | 2003-12-04 |
ZA200307324B (en) | 2005-02-23 |
ES2309167T3 (es) | 2008-12-16 |
PL362414A1 (en) | 2004-11-02 |
CN100404673C (zh) | 2008-07-23 |
WO2002069232A3 (en) | 2003-02-13 |
US20040180386A1 (en) | 2004-09-16 |
CN1493052A (zh) | 2004-04-28 |
EP1998266A3 (de) | 2009-02-11 |
EP1366455B1 (de) | 2008-07-02 |
JP2004523754A (ja) | 2004-08-05 |
AU2002256624B2 (en) | 2007-12-06 |
US7430476B2 (en) | 2008-09-30 |
WO2002069232A2 (en) | 2002-09-06 |
JP4279554B2 (ja) | 2009-06-17 |
KR20030075201A (ko) | 2003-09-22 |
KR100899970B1 (ko) | 2009-05-28 |
EP1998266A2 (de) | 2008-12-03 |
EP1366455A2 (de) | 2003-12-03 |
AU2002256624B8 (en) | 2002-09-12 |
HUP0303199A2 (hu) | 2003-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE400030T1 (de) | Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität | |
ATE535615T1 (de) | Chemisch modifizierte nukleinsäuren und methode zur kopplung von nukleinsäuren an einen festen träger | |
ATA1302001A (de) | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen | |
ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
ATE549347T1 (de) | Gene von säugetiere, und damit verbundene reagentien, methoden | |
DE69737023D1 (de) | Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
IL165952A0 (en) | Method for identifying tumors that are responsive to treatment with anti-erbb2 antibodies | |
DE69233204D1 (de) | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung | |
DK1373301T3 (da) | Reducering af immunogeniciteten af fusionsproteiner | |
DE69840448D1 (de) | 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung | |
UA93855C2 (ru) | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе | |
DK1253201T3 (da) | Kyllingeanæmivirusmutanter og vacciner baseret på det virale protein VP3 eller sekvenser af dette virus kodende derfor | |
ATE533837T1 (de) | Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen | |
DE69939903D1 (de) | Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav-vektoren mit hohem titer | |
ES2079621T3 (es) | Procedimiento de identificacion o de titulacion de proteinas y aplicaciones. | |
MX2022010664A (es) | Materiales y métodos para modular una respuesta inmunitaria. | |
DE60127715D1 (de) | Polypeptide zur auslösung einer immunreaktion gegen krebs | |
ATE328102T1 (de) | Verfahren zur herstellung von proteine | |
DE1105508T1 (de) | Verfahren zur reinigung von proteinen und biomolekül- oder proteinkomplexen | |
DE60329594D1 (de) | Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe | |
DE50311212D1 (de) | Verfahren zur herstellung von perfluoralkylphosphinen und deren verwendung als perfluoralkylierungsreagenzien | |
ATE292192T1 (de) | Verfahren zur herstellung und immobilisierung von nukleinsäure auf einem silan-modifizierten festträger | |
ATE339186T1 (de) | Methode zur herstellung von mikropartikeln enthaltend biologisches material | |
ATE269905T1 (de) | Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |